RxDoctor Payments Data

Abbas Ali, MD

Cardiovascular Disease · Clermont, FLNPI 1801899158

Payments from drug & device makers

$15,578in general payments, 2019–2025

Across 71 payments — averaging $219.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$12K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$215
  • Abiomed$129
  • Johnson & Johnson$123
  • Cvrx, Inc.$118
  • plus $430 from 10 others

What the payments were for

  • Travel & lodging$2,06162%
  • Food & beverage$1,27138%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,578 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$83,833
Medicare patients
1,006
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$49,368
JardianceEmpagliflozin34$42,270
EntrestoSacubitril/Valsartan31$31,069
Repatha SureclickEvolocumab29$28,295
XareltoRivaroxaban15$26,687
FarxigaDapagliflozin Propanediol26$22,586
OzempicSemaglutide11$10,354
Ranolazine ErRanolazine17$1,611
Amiodarone Hcl13$1,122
Isosorbide Mononitrate ErIsosorbide Mononitrate71$1,036
Rosuvastatin Calcium71$856
Metoprolol Succinate68$790
Nitroglycerin41$453
Lisinopril73$431
Warfarin Sodium23$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$49,36849 claims
Boehringer IngelheimJardiance$83$42,27034 claims
NovartisEntresto$58$31,06931 claims
Johnson & JohnsonXarelto$123$26,68715 claims
AstraZenecaFarxiga$14$22,58626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →